Compare PSIX & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSIX | NRIX |
|---|---|---|
| Founded | 1985 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | N/A | 2020 |
| Metric | PSIX | NRIX |
|---|---|---|
| Price | $60.01 | $16.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | ★ $98.76 | $29.46 |
| AVG Volume (30 Days) | 539.0K | ★ 702.7K |
| Earning Date | 01-01-0001 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $76,987,000.00 |
| Revenue This Year | $50.35 | N/A |
| Revenue Next Year | $20.10 | $26.32 |
| P/E Ratio | $17.20 | ★ N/A |
| Revenue Growth | N/A | ★ 99.31 |
| 52 Week Low | $18.10 | $8.18 |
| 52 Week High | $121.47 | $22.50 |
| Indicator | PSIX | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 34.86 | 49.16 |
| Support Level | $49.78 | $16.02 |
| Resistance Level | $76.03 | $16.49 |
| Average True Range (ATR) | 7.95 | 0.78 |
| MACD | -3.73 | 0.11 |
| Stochastic Oscillator | 4.07 | 90.00 |
Power Solutions International Inc is an America-based company that manufactures, distributes, and services power systems that run on nondiesel fuels, including natural gas, propane, and gasoline. The company's products are designed to meet emission standards imposed by environmental regulatory bodies like the Environmental Protection Agency. Its products are distributed to a wide range of industrial original equipment manufacturers that supply equipment to sectors including power generation, oil and gas, material handling, airport ground support, agricultural, turf, construction and irrigation. The company generates majority of its sales from United States.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.